• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Conference Coverage
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Resources
CBD in Pets
CE Requirements by State
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Equine intra-articular therapy (Proceedings)

November 1, 2009
Jennifer Brown, DVM, DACVS

Guidelines for equine intra-articular therapy

Therapeutic goals

• Eliminate lameness (pain)

• Disease modification

• Chondroprotection

What are we treating?

• Inflammation

• Mechanical stress

• Synovial fluid changes

• Cartilage pathology – breakdown

• Degenerative changes

Target areas for treatment

• Synovium

• Synovial fluid

• Articular Cartilage

• Sub-chondral Bone

Challenges of medical management

• Specific joint involved

• Stage of lesions

• Current and intended use of the horse

• Age of the horse

• Treatment cost

• Response to therapy

• Regulations

What we use

• Steroids

     o Methylprednisolone acetate

     o Triamcinolone

     o Betamethasone

• Sodium hyaluronate

• Polysulfated glycosaminoglycans

• Interleukin-1 Receptor Antagonist

• Autologous Stem Cell

Corticosteroids

• Effects on Inflammation

     o Inhibition of prostaglandin synthesis

     o Phospholipase A2 inhibition

• Disease-modifying effects

     o Inhibition of NF-κβ

     o Decrease cytokine production

     o Decrease IL-I, TNF α

     o Inhibit MMP production

     o Decrease fibrin deposition

• Effects of IA Corticosteroids on target Areas

     o Synovium/Synovial Fluid

          • Reduce synovitis

               - Reduced synovial effusion (MPA) (Van Pelt RW. JAVMA 143:738-748, 1963)

               - Decrease synovial membrane permeability (Eymontt et al. J Rheum 9:198-203 1982)

               - Decreased total protein, increased viscosity, increased HA concentration (MPA) (Chunekamrai S et al. AJVR 50:1733-1741 1989)

          • Inhibit interleukin-1 synthesis by synovial lining cells

          • May improve cartilage nutrition by controlling severity of synovitis

               - Enable return of normal synovial fluid properties

               - Improve fluid exchange within the joint

          • Increase proteoglycan concentrations (Roneus B et al. Zentralbl Veterinarmed; 40:10-16 1993)

          • Increase in HA concentrations (Tulamo RM. AJVR; 52:1940-1944 1991)

     o Cartilage

          • Reduce matrix metalloproteinase activity in osteoarthritic cartilage in vitro (Richardson DW et al. Inflamm Res; 52:39-49 2003)

               - Dose dependent

          • Inhibit synthesis of metalloproteinase activators like plasminogen activator or plasmin

          • Reduced cartilage damage in OA models in horses (Frisbie DD et al. EVJ 29:349-359 1997)

          • Deleterious effects of steroids on cartilage:

               - Inhibition of proteoglycan synthesis (Trotter et al. AJVR 52:83-87 1991)

               - Dose dependent (Todhunter RJ et al J Rheum 23:1207-1213, 1996)

          • Depresses total protein and collagen synthesis at high doses (Todhunter RJ et al J Rheum 23:1207-1213, 1996)

          • Decrease in Safranin-O staining

Advertisement

               - Estimate of matrix GAG content (Trotter et al. AJVR 52:83-87 1991)

          • Decreased chondrocyte metabolism (Chunekamrai S et al. AJVR 50:1733-1741 1989)

          • Chondrocyte necrosis and hypocellularity (MPA) (Chunekamrai S et al. AJVR 50:1733-1741 1989)

          • Decreases in cartilage proteoglycan can be prolonged (Chunekamrai S et al. AJVR 50:1733-1741 1989; Trotter et al. AJVR 52:83-87 1991)

     o Bone

          • Most effects on bone are associated with systemic administration

               - Adrenal suppression

          • Decreases osteophyte formation and fibrillation (Williams JM et al; Arthritis Rheum 28:1267-1273 1985)

• Associated Complications of Steroid Use

     o Steroid Arthropathy

          • Defined as acceleration of degenerative changes within joint associated with steroid use

               - Loss of joint space

               - Instability of the joint

               - Osteonecrosis

               - Peri-articular osteophytosis

          • Low incidence

               - <1% in humans (Hollander JL. MD Med J; 19:62-66)

               - May be progression of degenerative joint disease/osteoarthritis irrespective of steroid use

               - Especially in cases where exercise is continued

     o Post-Injection Flare

           • Acute inflammatory response

               - Synovial effusion

               - Increased WBC

          • Heat, pain, swelling, lameness

          • 8-24 hours post-injection

          • 2% incidence in people (Hollander JL MD Med J 19:62-66, 1970)

               - Low incidence in horses (Pool RR et al Proc AAEP 26:397-415 1980)

               - Up to 13 days post-injection

          • Vehicle related

               - Less prevalent with branched chain esters

     o Potentiation of infection

          • Signs not obvious immediately following injection

               - Clinical signs masked for up to 3 days (Tulamo RM et al EVJ 21:332-337, 1989)

          • Infections following steroid injections can be devastating

               - Severe joint pathology

          • Incidence unknown in horse

               - Less than 1% in humans (Charalambous CP et al Clin Rheum 22(6):386-90, 2003)

               - 12% in knee

     o Laminitis and IA Steroids

          • Triamcinolone acetonide

               - Most often implicated

               - Evidence of direct correlation is tenuous

                    • Retrospective analysis

                         o 0/201 horses treated with 40-80 mg doses

                         o 4/205 developed laminitis

                         o All 4 had prior history of laminitis

               - Alters glucose metabolism = hyperglycemia (French et al. J vet Pharm Therap 23:287-292, 2000)

                    • Given IV or IM

                         o Effects persist

                         o 3-4 days at low dose (0.05 mg/kg)

                         o 8 days at high dose (0.2 mg/kg)

                    • Laminitis associated with altered glucose metabolism (Pass et al. EVJ suppl 26:133-138, 1998)

• Doseage Guidelines (whole-body dose)

     o Triamcinolone < 18 mg

     o Methylprednisolone acetate < 200 mg

     o Betamethasone < 30 mg

• Potency per Unit Dose

     o Flumethasone (most potent)

     o Isoflupredone

     o Betamethasone

     o Triamcinolone

     o Methylprednisolone (least potent)

• Duration of Action

     o Short-acting Corticosteroids

          • Hydrocortisone, Flumethasone

     o Longer-acting Corticosteroids

          • Triamcinolone, Betamethasone, Methylprednisolone acetate

     o Water solubility is irrelevant

     o Rate of hydrolysis of ester is critical

• Triamcinolone acetonide

     o Medium length intra-articular half-life (1-5 days)

     o 6-12 mg/joint

     o 18 mg total body dose

     o Has shown the most positive effects of the steroids studied

          • In vitro (Richardson DW et al. Inflamm Res; 52:39-49 2003)

               - Inhibit synthesis of MMP and other proteinases

     • In OCF model (Frisbie DD et al. EVJ 29:349-359 1997)

               - Minimized development of OA

• Methylprednisolone acetate (Depo-Medrol)

     o Dose dependent balance between combating inflammation, yet maintaining healthy joint environment

     o 10 - 40 mg / joint

     o Long acting (intra-articular half-life 1 month)

     o 120 mg total body dose

• Betamethasone (Betavet)

     o Potent

     o Medium to long duration of action

     o 16 mg/joint (Foland JW et al. Vet Surg 23:369-376 1994)

          • In exercised and non-exercised horse no deleterious affects on cartilage in OCF model

          • Can affect proteoglycan synthesis at low doses (Frean SP et al J Vet Pharm and Ther; 25:289-298 2002)

     o 30 mg total body dose

• Steroid Application

     o Choose wisely

     o Low dose

          • Most affects are in high-dose models

     o Rest after use

          • 24 hours in human patients prolongs response (Chakravarty K et al Br J Rheumatol 33:464-468 1994)

          • Impact of exercise on compromised joint

     o Limit repeated doses

          • More effects observed in studies with repeated doses

• Where are we now in regards to steroid use?

     o Low doses of corticosteroids have chondroprotective properties without marked deleterious effects on chondrocytes

     o Still have much to learn

          • Dose?

          • Frequency of administration?

          • Enhance efficacy if combined with HA or growth factor therapy?

Sodium hyaluronate

• Hyaluronic Acid

     o HA = hyaluronan = hyaluronic acid

     o Long unbranched nonsulfated glycosaminoglycan

     o Synthesized by

          • Type B synoviocytes

          • Chondrocytes

               - Component of extra-cellular matrix

     o Functions within the joint:

          • Viscoelasticity of joint fluid

          • Boundary lubrication

          • Modulates chemotactic response

• Sodium Hyaluronan (HA)

     o Linear polydisaccharide

     o Original concept - viscosupplementation

     o Most effective in treatment of acute synovitis

     o Mechanisms remain unclear

          • Anti-inflammatory effects

               - Suppression of cytokines and proteinases (Takahashi K et al. Osteoarthritis Cartilage; 7:182-190 1999)

          • Stimulation of endogenous HA production

     o Mechanisms of action

          • Steric hindrance

          • Scavenge free radicals

          • Reduction of bradykinin and prostaglandin

          • Increase in endogenous HA synthesis via cAMP levels

     o HA Choices

          • Does size matter?

               - Hylartin V (3.5,000,000 Da)

               - Legend (1,000,000 Da)

               - Hyvisc (1,000,000 Da)

               - Hyalovet (400,000 Da)

               - Synacid (150,000 Da)

          • Conflicting evidence

               - Differences between in vivo and in vitro work

               - Difference between studies using OA models

          • Recommendation is to use products between 500,000 and 2,000,000 Da MW

     o Combination Treatment

          • With steroids:

               - Synergistic beneficial effect

               - More long-lasting clinical effect (Rydell NW et al. Acta Vet Scand 11:139-155 1970)

               - Combination helps prevent changes associated with steroids (Roneus B et al Zentralbl Veterinar med A 40:10-16 1993)

Polysulfated glycosaminoglycan (Adequan)

• Semi synthetic preparation of bovine trachea

     o Composed primarily of chondroitin sulfate

• Stimulation of production of HA (synoviocytes)

• ±Increase synthesis of proteoglycans and collagen by chondrocytes

• Inhibit degradative enzymes

     o nMMP

     o Plasminogen activators

     o Lysosomal elastase

     o Cathepsin

• Adverse Effects of PSGAG

     o Increases activated partial thromboplastin, prothrombin, and activated clotting times in dogs at 5 and 25 mg/kg (Beale et al., 1990)

     o Thrombocytopenia (human)

     o IA use: Increased minimum inhibitory concentration of antibiotics effective in vitro against S. aureus (Gustafson et al., 1989)

Interleukin-1 receptor antagonist (IRAP)

• Autologous Conditioned Serum

     o Interleukin-1 Receptor Antagonist

          • Competes with Interleukin-1 for binding

          • Prevents activation of receptor

          • Experimental evidence for decreasing joint inflammation is strong

     o Increase IRAP in serum by incubation with chromium beads

          • Stimulate monocytes (human)

               - ↑ IRAP_____140x

               - ↑ IL-4, IL-10___2x

               - IL-1β, TNF-α__0x

          • Improved lameness

          • Decreased synovial membrane hyperplasia

          • Better for acute synovitis

• Levels of IRAP???? Cost!

• Carpal chip model of OA

     o IL-1 Ra level increased after processing:

          • 234 pg/ml v. 45 pg/ml

     o Improved histologic score

     o Synovial fluid IL-1 Ra increased over time

          • Stimulates endogenous production of IL-1 Ra

Autologous stem cells

• Cell-based Therapies

• Direct injection of cells

     o Nucleated cell fraction from adipose tissue (VetStem)

     o Cultured bone marrow mesenchymal stem cells

• VetStem

     o Joint Injection

          • 56.7% (34/60) returned to full work at prior level and 26.7% (16/60) returned to full work at a reduced level

          • 50/60 back in work

Related Content:

Equine MedicineRespiratory Medicine
SoCal Equine Hospital installs innovative CT scanner
SoCal Equine Hospital installs innovative CT scanner
Donkey treated for oleander poisoning
Donkey treated for oleander poisoning
New study finds promising results in treating equine swollen limbs with compression therapy
New study finds promising results in treating equine swollen limbs with compression therapy

Advertisement

Latest News

An update on copper concerns in pet foods

Dental hacks to make every case more manageable

Q&A with a keynote: Walter Brown, RVTg, VTS, ECC

News wrap-up: This week’s headlines, plus dvm360® launches its first CE podcast

View More Latest News
Advertisement